Grants>Cancer

Wipe Out Kids’ Cancer, Inc. Research Grant Program

Application deadline: August 30, 2013

Wipe Out Kids’ Cancer, Inc. (WOKC) is a Dallas-based nonprofit organization founded in 1980 dedicated to raising awareness and funding pediatric cancer research on a national basis.  WOKC’s mission is to work relentlessly for the day when all children are living cancer free.

One of the main goals of WOKC is to find cures through research.  To meet this goal, WOKC provides grants to support meritorious research ranging from basic laboratory investigation to clinical management of pediatric cancers.  For all awarded grants, collaboration with a pediatric cancer treatment center and an institution with basic and/or clinical research programs are encouraged.

Research Grants

Policies and Guidelines

Research Grants are offered to encourage the development of new information that contributes to the understanding, treatment, and cure of pediatric cancers.  In addition, consideration will be given to those projects that provide insight into information that may contribute to the development of new therapies for pediatric cancers.  All proposals must be hypothesis driven, and sufficient preliminary data must be provided to justify the WOKC support.  Information derived from these studies should have high potential for sustainable future support from other funding agencies, such as the National Institutes of Health (NIH).

Research Grant applications should focus on basic science research or clinical research.  Those proposals that include methodologies requiring sampling of materials from human subjects will be considered under this mechanism only if the sampling method constitutes minimal patient risk and are approved by the clinical/research institutions internal review board.  All other projects utilizing human subjects must submit a Clinical Research Letter of Intent.

Applications for Research Grants are being accepted with the following stipulations:

Funding amount from $50,000 up to $150,000, including no more than 8% indirect costs, may be requested.

Grants may be approved for up to a 1 year period of funding.

Because grants cover only one year of research, likelihood of future funding from other sources will be considered and should be explained by the applicant.

Applicants must be independent investigators, or clinical or research receiving direct oversight/mentorship by an independent investigator.

Applicants need not be U.S. Citizens or hold a U.S. permanent visa to apply for this award.

International applicants and institutions are required to submit additional information in accordance with U.S. anti-terror restrictions.

SUBMISSION GUIDELINES

Application Deadline: August 30, 2013 at 5:00pm (Eastern Time)

Applications must be sent electronically with any signatures scanned to Evelyn Costolo at ecostolo@wokc.org.  Hard copies will not be accepted.

Do not submit an incomplete application. An application will be considered incomplete if it fails to comply with instructions or if the material is insufficient to permit adequate review.

Revisions, insertions or appendices to applications will not be accepted after the receipt date unless agreed to by WOKC’s Grants Committee. Even if a part of an application is approved for late submission, there is no guarantee that the application will be reviewed. Only Human Subjects Certification, Use of Animals Certification, and Recombinant DNA Approval will be accepted apart from the body of the grant application if they are not available at time of submission.

Requests to submit supplemental data must be received before November 1st.

Urology Care Foundation/Ferring Pharmaceuticals Urology Research Success Award in Prostate Cancer Research

The application package must be SUBMITTED by email no later than 11:59 p.m. LOCAL time on Monday, July 8, 2013.

The preponderance of urologic research is funded through federal and state governments and the philanthropy of private foundations and non-profit organizations. The competition for these limited funds is extremely intense. Many projects are funded through a series of grants, thus young scientists and senior researchers may experience gaps in funding while awaiting peer review and/or approval for a new grant to support the next phase of research.

Part of the mission of the Urology Care Foundation is to expand and support research in urologic diseases. Thanks to the generosity of Ferring Pharmaceuticals, Inc., the Urology Care Foundation is proud to offer the Urology Care Foundation/Ferring Pharmaceuticals Urology Research Success Award in Prostate Cancer Research. The award will provide up to $10,000 designed to assist a urology researcher in continuing vital urology research efforts while awaiting new funding. Research supported by this award ultimately will contribute to helping those who suffer from the effects of prostate cancer.

Please submit all application docurments to grants@urologycarefoundation.org.

Call for Applications: 2014 Research Grant Awards Program of the Skin Cancer Foundation

The Skin Cancer Foundation is now accepting applications for support of pilot research projects related to skin cancer.  The Foundation funds basic research and clinical studies which address improved methods of prevention, detection, and treatment of skin cancer.  Researchers are invited to submit applications for one-year projects to be conducted within the Dermatology departments of medical institutions within the U.S.

Since its founding in 1979, The Skin Cancer Foundation has set the standard for educating the public and the medical profession about skin cancer, its prevention by means of sun protection, and the need for early detection and prompt, effective treatment.  It is the only international organization devoted solely to combating the world’s most common cancer.  The Foundation’s mission is to decrease the incidence of the disease by means of public and professional education, and research.

Application Requirements

The deadline for applications is Friday, October 4, 2013.

Applications must be received by this date to be considered.

Six copies of the completed application form (and any supporting documentation) should be mailed to The Skin Cancer Foundation at 149 Madison Avenue, Suite 901, New York, NY 10016.

Note:  Applications submitted via e-mail will not be accepted.

Only applications for research projects relevant to skin cancer will be accepted for consideration.  The Foundation's Research Grant Awards Program is intended for pilot projects, which, if successful, can be developed to the point where they are eligible for larger grants from other sources.  Research must be conducted by dermatology residents, fellows, and young faculty (5-10 years post first academic appointment) from institutions within the U.S.  Preference is given to projects that address, at the basic science and clinical level, improved methods of prevention, detection, and treatment of skin cancers. 

The Foundation is pleased to increase its pledge for the research program for 2014.  Levels of funding for research grants are:

(3) - $25,000, (1) - $15,000, (1) - $10,000

Funding is based on the scope of the research project.  Please specify the grant amount for which you are applying on page 4 under “Budget”. It is the Foundation's policy not to fund overhead or indirect costs.

Grant recipients will be notified by Friday, December 6, 2013.  Presentations will take place at the Foundation's Grant Awards Reception on Sunday, March 23, 2014, held at the Annual Meeting of The American Academy of Dermatology, in Denver,CO. Grantees must be present at the reception to accept their awards in person.

Children’s Leukemia Research Association Research Grant Program

Each year, CLRA's Medical Advisory Committee, consisting of prominent internationally known and respected hematologists, reviews submitted research proposals from doctors nationwide. 

Using your contributions, we fund research grants for doctors who are conducting the most promising research into leukemia, in the hopes of isolating the causes and finding a cure for this dread disease.

The objectives of this committee are to direct the funds of the Association into the most promising projects, and where funding would not duplicate other funding sources.

With your help, we are getting closer every day! Because of the support of friends like you, the scientific community is making incredible strides in developing chemotherapy regimens that are extending the lives of leukemia patients. Not everyone under treatment goes into remission but our research grants are funding the examinations into why this is so, and how we can continue to combat leukemia.

How the CLRA Research Grant Program Works

Any doctor at the Ph.D. or MD level who is involved in research towards finding the causes and cure for leukemia may apply.

Simply complete online form and print, or call or write to us for one.

Please submit an original and three copies of your application prior to June 30 of each year.  It is then reviewed by our Medical Advisory Committee. A decision is made by the following calendar year.

In order that we may fund as many projects as possible, grants are limited to a maximum of $30,000 each, subject to availability of funds.

CLRA
585 Stewart Avenue
Suite 18
Garden City, NY 11530

Tel:  516-222-1944
Fax: 516-222-0457

info@childrensleukemia.org

Call for Applications: Alex’s Lemonade Stand Foundation Bridge & Springboard Grants

Bridge Grant

Alex’s Lemonade Stand Foundation introduces a new funding opportunity for researchers whose projects are in jeopardy due to the decreased funding available from the National Institutes of Health (NIH). ALSF’s Bridge Grants are intended to keep scientist’s projects on track while they reapply for NIH funding to ensure novel childhood cancer research projects are not compromised. ALSF’s Bridge Grant awards will provide $100,000 for 12 months to be used for supplies, personnel or the Principal Investigator’s salary.

Eligibility Requirements:

Project must have been previously funded by an NIH R01, R03, R21 or P01 Award. (R01 Supplements are not eligible for Bridge Grants.)

Researchers must have applied to the NIH for an R01 or P01 renewal for an ongoing project or to continue the project via new R01 or P01 within the last 6 months.

The application must have been scored ≤25th percentile, but outside of the agency’s fundable range.

Applicants must be reapplying for an R01 or P01 Award from the NIH within the next two NIH Grant cycles.

Projects must be aligned with ALSF’s mission, thus focused on better diagnosing or curing childhood cancers.

Funds may be used for supplies, personnel or PI’s salary and may not exceed $100,000. ALSF does not pay indirect costs. 
  
Application Process:

To expedite the application progress, ALSF’s Scientific Advisory Board will review the previously reviewed NIH application along with any changes that have been made in response to feedback from NIH reviews.

A cover letter, summary statement, response to NIH critique and budget will be required by all applicants.

All applications must be submitted via ALSF’s online application.
    
Springboard Grant

ALSF’s offers the Springboard Grant in response to cut-backs in National Institutes of Health (NIH) funding of new R01 and P01 applications. The Springboard Grant is designed to jump-start new projects with high impact potential for childhood cancer research while other funding is sought. Awards will provide $100,000 for 12 months to be used for supplies, personnel or the Principal Investigator’s salary.

Eligibility Requirements:

Researchers must have applied to the NIH for an R01 or P01 award within the last 6 months. (R01 Supplements are not eligible for Springboard Grants)

Applications must have scored ≤20%, but outside of the agency’s fundable range.

Applicants must be reapplying for an R01 or P01 award from the NIH within the next two NIH Grant cycles.

Projects must be aligned with ALSF’s mission thus focused on better diagnosing or curing childhood cancers.

Funds may be used for supplies, personnel or PI’s salary and may not exceed $100,000. ALSF does not pay indirect costs. 

Application Process:

To expedite the application progress, ALSF’s Scientific Advisory Board will review the previously reviewed NIH application along with any changes that have been made in response to feedback from NIH reviews.

A cover letter, summary statement, response to NIH critique and budget will be required by all applicants.
All applications must be submitted via ALSF’s online application.

Alex's Lemonade Stand Foundation for Childhood Cancer  333 E. Lancaster Ave., #414 Wynnewood, PA 19096

Ph: 610.649.3034

Fax: 610.649.3038

Request for Proposals: International Innovation Grant

The International Innovation Grant provides research funding in support of novel and innovative projects that can have a significant impact on cancer control in low- and middle-income countries.

The International Innovation Grant is a one-year research grant of up to $20,000 that is awarded and paid directly to a nonprofit organization or governmental agency in a low-income or middle-income country. The grant may be used by the organization only for the approved, budgeted costs of the research project. Each grant will have a Principal Investigator who is an ASCO member, is affiliated with the Grantee Organization, and is a resident of the low-income or middle-income country.

International Innovation Grants are hypothesis-driven research grants that fund a specific research project that may result in the discovery of new knowledge about how to advance cancer control in a low- or middle-income setting.  It is anticipated that novel approaches and clinical designs proposed for this grant may differ from what would be considered standard practice within high-income settings.  Grantee Organizations and Principal Investigators will be expected to share and disseminate the knowledge gained during their research project.

The online system will open for Letter of Intent submission on July 1, 2013. All Letters of Intent must be submitted by August 1, 2013.

Questions? Read our Frequently Asked Questions document:

http://www.conquercancerfoundation.org/sites/conquercancerfoundation.org/files/international_innovation_grant_faq_5-1-2013.pdf

If that doesn’t answer your question, email grants@conquercancerfoundation.org.

2014 International Innovation Grant Timeline:

May 1, 2013 RFP is Released for 2014 International Innovation Grant

July 1, 2013 Online Application System Opens for Submitting Letters of Intent

August 1, 2013 Letters of Intent Due

October 3, 2013 Invited Full Applications Due

December 2013 Grant Recipients Announced

January 1 - December 30, 2014 Grant Project Period

Request for Application: Cutaneous Lymphoma Foundation’s CLARIONS Research Awards Program

The signature funding initiative of the Research Awards Program (RAP), is the CLARIONS Grant Program, which stands for Curing Cutaneous Lymphoma by Advancing Research, Innovation and Offering New Solutions.  This research grant program supports investigators interested in conducting innovative cutaneous lymphoma research.   These grants will help uncover causes and improve the treatment and quality of life for patients. Discovering new avenues for better therapies and, one day, a cure for cutaneous lymphoma are key goals of this program.

Research Funding Priorities

Eligibility and Requirements

Investigators at all levels, from clinical and post-doctoral fellows to established investigators, are eligible to receive
awards. Medical students and graduate students are not eligible. Non-U.S. investigators are eligible and the research funded by the RAP can be conducted at non-U.S. institutions. Investigators must be members of an established and recognized academic institution. All research projects involving human subjects must receive IRB approval.

Award Amounts

Each year the CLF will provide two $25,000 awards, renewable for 1 year contingent upon approval by the CLF
Board of Directors based upon the CLF Scientific Review Board’s review and recommendation.

A small indirect cost amount between $1,000-$2,000 is allowable.

The CLF’s RAP seeks to fund innovative research in all areas of cutaneous lymphomas with particular interest in:

-- Etiology and risk factors of cutaneous lymphomas.

-- Measures of disease impact on individuals and populations affected by cutaneous lymphomas.

-- Translating discoveries into diagnostic and therapeutic advances in cutaneous lymphomas.

-- Optimizing therapies for cutaneous lymphomas.

-- Improving quality of life for individuals with cutaneous lymphomas

2013 Calendar of Award Events

January 31 -  Public announcement of Request for Application (RFA)

July 31 -  Application deadline

August - October - Scientific Review Board review

November - Recipients notified of award

December - Grant awards announced at ASH meeting

January, 2014 - Disbursement of Award and beginning of new award cycle

Cutaneous Lymphoma Foundation
PO Box 374
Birmingham, MI 48012-0374

Telephone: 248-644-9014

Fax: 248-644-9014

Call for Cancer Projects: Repurposing of Drugs - Breakthrough in Cancer Treatment

Funding Cancer Projects

Reliable Cancer Therapies (RCT) announces € 300 000 for projects repurposing existing drugs for cancer treatment.  The drugs must have been developed and approved for other indication(s). Relevant clinical trial endpoints (cancer survival & tumor response) should be the primary research assessments.

RCT also promotes collaborative research projects between researchers at different universities and/or organisations.

About the Call for Applications

• Medical Degree required for Principal Investigator (PI) or co-PI

• 1 application per PI

• Resubmission is allowed (please indicate the reason for previous decline)

• Set up of proposal:

◦ Application form: maximum 2 pages

◦ in appendix 1: biography & references of the PI and co-PI

◦ in appendix 2: overview of the budget (including salaries, supplies, equipment, patient care costs, and other expenses).

• If your cancer project is selected in the first round, detailled information will be requested for consideration of the final award selections.

• Approved proposals will be supported with a maximum of  € 300 000 for 3 years.

Reliable Cancer Therapies (RCT) is a non-profit organization based in Switzerland that provides research-based information on cancer therapies and selectively funds the development of promising therapies.

RCT investigates information on cancer therapies for evidence to then inform the public about evidence-based cancer treatment choices. We help cancer patients and caregivers to structure and absorb the complex nature of cancer information for their decision-making on registered complementary or alternative therapies.

RCT is continuously looking for cancer therapies that have never been thoroughly examined and consider financing cancer treatments that can be deemed promising based on measurable results.

Application Deadline

Application deadline is June 28, 2013 at 8am GMT. Incomplete or late applications will not be considered.

Please submit applications to Ann-Christine Moenaert (info@reliablecancertherapies.com)

RCT will review the applications internally with the support from our appropriate external experts by August 14, 2013. If the project is selected in the first round, more detailled information will be requested by September 13, 2013.  Final decisions will be made on October 4, 2013.

Contacts at RCT

Please direct any technical questions to Ann-Christine Moenaert (info@reliablecancertherapies.com)

Please contact Gauthier Bouche, MD (info@reliablecancertherapies.com) for any clinical or scientific questions.

Call for Applications: Meso Foundation Research Grants

The Meso Foundation (formerly known as MARF) is the non-profit dedicated to ending the suffering caused by mesothelioma. We are the international collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to:

·  Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso treatment specialists, and providing them assistance, emotional support and community with others;

·  Raise awareness of meso, and advocate that the public and private sectors partner in the effort to cure it by directing the resources needed to stop this global tragedy; and

·  Fund the highest quality and most promising meso research projects from around the world through rigorous peer-review. To date we have funded 86 projects, from six different countries, totaling over 8.2 million dollars.

The Meso Foundation offers research grants for two years up to $50,000 per year. Eligible projects may relate to benchwork, translational or clinical research that is not presently funded or pending review and may be conducted through any not-for-profit academic, medical or research institution. The Foundation will review and monitor the project's progress and results, requiring semi-annual disposition of funds reports, a ten month progress report, a presentation at the Foundation’s Symposium and a full progress report at the close of the project. The Foundation seeks exceptional projects for which the Foundation's funding is demonstrated to be essential and not duplicative. Please be advised that the Foundation does not pay institutional indirect costs.

Funded researchers will also be entitled to facilitated access to the National Mesothelioma Virtual Bank (NMVB),www.mesotissue.org.They will receive expedited review of requests to use the NMVB, and they will have direct, no-cost access to materials in the bank, as well as enhanced collections from the main sites of materials.

Encouraged projects include, but are not limited to, investigations of:

1. Strategies for early detection of new or progressive disease;

2. Definition of targetable differences between normal and transformed mesothelium and development of novel strategies for treatment;

3. Therapeutic intervention, including but not limited to;

a. Immune Response Targeted Therapy

b. Novel chemotherapeutic compounds

c. Novel radiation or surgical techniques

4. Determination of clinical/molecular determinants for prognosis

Applications will be considered for funding by the Meso Foundation’s Science Advisory Board comprised of doctors and researchers who work around the world within the mesothelioma field. These members will review and score the research proposals based on the following criteria. The applications will be ranked numerically and the highest scoring projects will be recommended to the Foundation’s Board of Directors for funding. Based on the funding available, awards will be granted.

Applications will be evaluated on the following criteria:

Significance - Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Investigator(s)- Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Innovation - Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Approach - Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, justified in terms of the scientific goals and research strategy proposed?

Environment - Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

Applications should be submittedthrough proposalCENTRAL.You will find the Mesothelioma Applied Research Foundation listed with the instructions and the application required. Applications are limited to 10 pages (not including biographies) and are due no later than August 2, 2013. Final award decisions will be made in December 2013 and all applicants will be notified of the outcome.

Request for Proposal: Desmoid Tumor Research Foundation

Submission deadline for Applications: June 30, 2013.

The Desmoid Tumor Research Foundation, Inc. (“DTRF”) seeks to advance the science related to desmoid tumors by:

• Funding research related to the diagnosis and treatment of desmoid tumors;

• Facilitating and enhancing the dialogue among members of the medical and scientific communities about research related to desmoid tumors;

• Providing informational support for desmoid tumor patients and their families and friends, and heightening awareness of desmoid tumor diagnosis and treatment.

The purpose of this Request for Proposal is to fund research that will advance the current scientific knowledge about desmoid tumors, resulting in the development of new treatment options and bringing us closer to our ultimate goal -- a cure.  Information about DTRF can be found at www.dtrf.org.

Approach

The Desmoid Tumor Research Foundation is the only foundation in the country dedicated to facilitating and funding research for a cure for desmoid tumors.  We fund research that uses cutting-edge science and creative clinical applications, in addition to novel approaches addressing potential leads based on prior research.  Researchers must be willing to collaborate with other scientists and institutions with similar interests.  Research proposals with additional sources of funding support are particularly desirable.

Grant Amounts and Restrictions

• Grants are awarded in amounts of up to $65,000 per year.

• Funds may only be used for personnel, supplies, equipment, and/or services.

• Use of funds for institutional overhead costs is strictly prohibited.

• Use of funds for indirect costs is strictly prohibited.

• Use of funds for project costs that are funded by other sources is strictly prohibited.

• Funding duration is a minimum of 1 year. 

Eligibility for grants:  MD, PhD, or equivalent degree, and sponsorship by an Exempt Organization as defined by Section 501(c)(3) of the Internal Revenue Code (the “Sponsoring Institution”).